tldrdailynews.com logo

Lilly widens early-access for unapproved obesity drug retatrutide

1 min read
Source: STAT
Lilly widens early-access for unapproved obesity drug retatrutide
Photo: STAT
TL;DR

Eli Lilly says it will allow more patients to apply for pre-approval access to retatrutide, the unapproved obesity drug, after previously granting access to a single 79‑year‑old patient; the company is reviewing requests from doctors in line with FDA guidance.

Topics:businesshealthcare#eli-lilly#expanded-access#fda-guidance#healthcare#obesity-drug#retatrutide
Share this article
  1. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug  STAT
  2. Eli Lilly to offer early access to next-gen obesity drug to some patients  Reuters
  3. Spotlight On: Good news and bad news for Lilly's triple agonist  FirstWord Pharma
  4. Retta Weight Loss: The Evidence, Benefits, and Realistic Expectations - View QMQEr6GEs  FC Bayern
  5. This Next-Gen GLP-1 Is Blowing Up the Black Market Economy  Marie Claire

Want the full story? Read the original reporting

Read on STAT